Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Greenberg

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Blood|May 15, 1996
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergyR S Negrin, R Stein, K Doherty, et al.
The Western Journal of Medicine|April 1, 1977
Remission maintenance therapy in acute myelogenous leukemiaS H Embury, L Elias, P H Heller, et al.
Blood|July 1, 1990
Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factorR S Negrin, D H Haeuber, A Nagler, et al.
Annals of Internal Medicine|June 15, 1989
Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trialR S Negrin, D H Haeuber, A Nagler, et al.
Annals of Internal Medicine|February 1, 1992
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphomaR Advani, N J Chao, S J Horning, et al.
Blood Cancer Journal|August 30, 2014
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)M A Sekeres, A S Swern, P Fenaux, et al.
Blood|September 6, 2001
Myelodysplastic syndromes standardized response criteria: further definitionB D Cheson, J M Bennett, H Kantarjian, et al.
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Blood|November 23, 2000
Report of an international working group to standardize response criteria for myelodysplastic syndromesB D Cheson, J M Bennett, H Kantarjian, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Chronic Myelogenous LeukemiaE Berman, R A Clift, E A Copelan, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Blood|May 15, 1996
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergyR S Negrin, R Stein, K Doherty, et al.
The Western Journal of Medicine|April 1, 1977
Remission maintenance therapy in acute myelogenous leukemiaS H Embury, L Elias, P H Heller, et al.
Blood|July 1, 1990
Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factorR S Negrin, D H Haeuber, A Nagler, et al.
Annals of Internal Medicine|June 15, 1989
Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trialR S Negrin, D H Haeuber, A Nagler, et al.
Annals of Internal Medicine|February 1, 1992
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphomaR Advani, N J Chao, S J Horning, et al.
Blood Cancer Journal|August 30, 2014
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)M A Sekeres, A S Swern, P Fenaux, et al.
Blood|September 6, 2001
Myelodysplastic syndromes standardized response criteria: further definitionB D Cheson, J M Bennett, H Kantarjian, et al.
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Blood|November 23, 2000
Report of an international working group to standardize response criteria for myelodysplastic syndromesB D Cheson, J M Bennett, H Kantarjian, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Chronic Myelogenous LeukemiaE Berman, R A Clift, E A Copelan, et al.
Pageof 8